Cardiff Oncology, Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
CRDF$0.80+0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
| PreferredStockShares | PreferredStockAmount | CommonStockShares | CommonStockAmount | Additional Paid-InCapital | AccumulatedOtherComprehensiveGain (Loss) | AccumulatedDeficit | TotalStockholders’Equity | |
|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2023 | 61 | $— | 44,677 | $4 | $409,343 | $(67) | $(339,541) | $69,739 |
| Modified-retrospective adoption of ASU 2020-06(1) | — | — | — | — | (793) | — | 793 | — |
| Issuance of common stock, net of expenses(2) | — | — | 21,708 | 3 | 53,404 | — | — | 53,407 |
| Stock-based compensation | — | — | — | — | 4,760 | — | — | 4,760 |
| Issuance of common stock upon exercise of stock options | — | — | 139 | — | 373 | — | — | 373 |
| Other comprehensive gain | — | — | — | — | — | 101 | — | 101 |
| Net loss | — | — | — | — | — | — | (45,431) | (45,431) |
| Balance, December 31, 2024 | 61 | — | 66,524 | 7 | 467,087 | 34 | (384,179) | 82,949 |
| Stock-based compensation | — | — | — | — | 5,693 | — | — | 5,693 |
| Issuance of common stock upon exercise of warrants(3) | — | — | 945 | — | 2,088 | — | — | 2,088 |
| Issuance of common stock upon cashless exercise of warrants | — | — | 553 | — | — | — | — | — |
| Issuance of common stock upon exercise of stock options | — | — | 283 | — | 493 | — | — | 493 |
| Other comprehensive gain | — | — | — | — | — | 16 | — | 16 |
| Net loss | — | — | — | — | — | — | (45,851) | (45,851) |
| Balance, December 31, 2025 | 61 | $— | 68,305 | $7 | $475,361 | $50 | $(430,030) | $45,388 |
(1)
See Note 2.
(2)
Net of expenses of$3.3 million.
(3)
Net of expenses of $0.2 million.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.